GSK-1070916
CAS No. 942918-07-2
GSK-1070916 ( GSK1070916 | GSK 1070916 )
产品货号. M16749 CAS No. 942918-07-2
Aurora B 和 C 的有效、选择性和 ATP 竞争性抑制剂,Ki 分别为 0.38 nM 和 1.5 nM。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ¥778 | 有现货 |
|
| 10MG | ¥1312 | 有现货 |
|
| 25MG | ¥2252 | 有现货 |
|
| 50MG | ¥3540 | 有现货 |
|
| 100MG | ¥5249 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称GSK-1070916
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述Aurora B 和 C 的有效、选择性和 ATP 竞争性抑制剂,Ki 分别为 0.38 nM 和 1.5 nM。
-
产品描述A potent, selective and ATP-competitive inhibitor of Aurora B and C with Ki of 0.38 nM and 1.5 nM, respectively; displays >250-fold selectivity over Aurora A; shows potent antiproliferative effect (EC50=7 nM) in A549 human lung cancer cells; causes inhibition of histone H3 phosphorylation at serine 10 in human colon cancer (Colo205) and tumor regression in human leukemia (HL-60) in mice.Ovarian Cancer Phase 2 Clinical.
-
体外实验GSK-1070916 potently inhibits Aurora B/INCENP and Aurora C/INCENP kinases with Kis of 0.38±0.29 and 1.45±0.35 nM, respectively, but is less potent against Aurora A/ TPX2 with a Ki of 492±61 nM. GSK-1070916 also inhibits FLT1, TIE2, SIK, FLT4, and FGFR1 with IC50 values of 42, 59, 70, 74, and 78 nM, respectively. Treatment of A549 human lung cancer cells with GSK-1070916 results in a potent antiproliferative effect (EC50=7 nM). GSK-1070916 inhibits a panel of tumor cell lines and is shown o inhibits the phosphorylation of HH3- S10 in all cell lines with average EC50 values ranging from 8 to 118 nM.
-
体内实验In nude mice implanted with human colon tumor (HCT116) xenografts, a single dose of GSK-1070916 administered i.p. inhibits HH3-S10 phosphorylation in a dose-dependent manner. Repeated i.p. administration of GSK-1070916 produces complete or partial antitumor activity in 4 of 8 tumor types [lung, A549; colon, HCT116; acute myelogenous leukemia (AML), HL60; and chronic myelogenous leukemia, K562], stable disease in 3 of 8 (colon, Colo205; lung, H460; and breast, MCF-7), and tumor growth delay in 1 of 8 tumor types (colon, SW620). Daily administration of GSK-1070916 is generally well-tolerated.
-
同义词GSK1070916 | GSK 1070916
-
通路Cell Cycle/DNA Damage
-
靶点Aurora Kinase
-
受体SIK| Aurora B-INCENP| Aurora C-INCENP| FLT1| Tie-2
-
研究领域Cancer
-
适应症Ovarian Cancer
化学信息
-
CAS Number942918-07-2
-
分子量507.6293
-
分子式C30H33N7O
-
纯度>98% (HPLC)
-
溶解度DMSO: ≥ 26.5 mg/mL
-
SMILESO=C(NC1=CC=C(C2=NN(CC)C=C2C3=C4C(NC(C5=CC=CC(CN(C)C)=C5)=C4)=NC=C3)C=C1)N(C)C
-
化学全称Urea, N'-[4-[4-[2-[3-[(dimethylamino)methyl]phenyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]-1-ethyl-1H-pyrazol-3-yl]phenyl]-N,N-dimethyl-
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Adams ND, et al. J Med Chem. 2010 May 27;53(10):3973-4001.
2. Hardwicke MA, et al. Mol Cancer Ther. 2009 Jul;8(7):1808-17.
3. Moy C, et al. J Transl Med. 2011 Jul 15;9:110.
产品手册
关联产品
-
MLN8054
一种有效的、选择性的、ATP 竞争性的、口服活性的 Aurora A 激酶抑制剂,IC50 为 4 nM。
-
Phthalazinone pyrazo...
Phthalazinonepyrazol 是一种有效的、选择性的、口服生物可利用的 Aurora-A 激酶抑制剂。 Aurora-A 在多种肿瘤类型中过度表达并表现出致癌活性。
-
Aurora Kinase Inhibi...
Aurora 激酶抑制剂 III 是 Aurora A 激酶的有效抑制剂 (IC50 = 42 nM)。1 它对 Aurora A 的选择性高于 BMX、BTK、IGF-1R、c-Src、TRKB、SYK 和 EGFR。
021-51111890
购物车()
sales@molnova.cn

